Next Article in Journal
Structure Enhancement Relationship of Chemical Penetration Enhancers in Drug Transport across the Stratum Corneum
Next Article in Special Issue
In Situ Focused Beam Reflectance Measurement (FBRM), Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) and Raman Characterization of the Polymorphic Transformation of Carbamazepine
Previous Article in Journal
Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles
Previous Article in Special Issue
Development and Validation of a Microbiological Agar Assay for Determination of Orbifloxacin in Pharmaceutical Preparations
Pharmaceutics 2012, 4(1), 58-70; doi:10.3390/pharmaceutics4010058

Recrystallization of Commercial Carbamazepine Samples—A Strategy to Control Dissolution Variability

,  and *
Industrial Pharmacy Lab, University of Basel, Mülhauserstrasse 51, Basel 4056, Switzerland
* Author to whom correspondence should be addressed.
Received: 5 December 2011 / Revised: 9 January 2012 / Accepted: 10 January 2012 / Published: 13 January 2012
(This article belongs to the Special Issue Solid Dosage Forms)
View Full-Text   |   Download PDF [3710 KB, uploaded 13 January 2012]   |   Browse Figures


Physical properties of commercial carbamazepine (CBZ) samples can significantly influence drug release and thereby jeopardize bioequivalence of the final dosage form. The aim of this study was to reduce variability in commercial CBZ samples by recrystallization. CBZ samples of four different suppliers were recrystallized in ethanol solution containing 1% polyvinylpyrrolidone (PVP). CBZ samples were analyzed by disk intrinsic dissolution rate (DIDR), X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). Recrystallized CBZ samples showed strongly reduced variability in DIDR compared to the untreated CBZ samples. Moreover, transformation process to CBZ dihydrate was inhibited; no dihydrate crystals were visible on compact surfaces after 8 h intrinsic dissolution measurement. Recrystallized CBZ samples showed no change in polymorphic form, however, particle size and shape was inhomogenous. In binary mixtures with microcrystalline cellulose, recrystallized CBZ samples again showed difference in drug release. This difference was associated with the inhomogenous particle size in the recrystallized CBZ samples. The results show that a controlled grinding step is required after recrystallization. We suggest the recrystallization in presence of 1% PVP followed by a controlled grinding step as a strategy to reduce dissolution variability in commercial CBZ samples.
Keywords: polyvinylpyrrolidone; polymer; intrinsic dissolution; polymorphism; transformation; morphology polyvinylpyrrolidone; polymer; intrinsic dissolution; polymorphism; transformation; morphology
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Flicker, F.; Eberle, V.A.; Betz, G. Recrystallization of Commercial Carbamazepine Samples—A Strategy to Control Dissolution Variability. Pharmaceutics 2012, 4, 58-70.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert